NYSE:PLX Protalix BioTherapeutics (PLX) Stock Price, News & Analysis $1.50 -0.01 (-0.66%) Closing price 07/28/2025 04:00 PM EasternExtended Trading$1.50 0.00 (-0.33%) As of 07/28/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Protalix BioTherapeutics Stock (NYSE:PLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PLX alerts:Sign Up Key Stats Today's Range$1.48▼$1.5250-Day Range$1.35▼$1.7252-Week Range$0.82▼$3.10Volume454,307 shsAverage Volume876,333 shsMarket Capitalization$119.41 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company Overview Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. Read More Protalix BioTherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScorePLX MarketRank™: Protalix BioTherapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 545th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingProtalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageProtalix BioTherapeutics has received no research coverage in the past 90 days.Read more about Protalix BioTherapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth3,000.00% Earnings GrowthEarnings for Protalix BioTherapeutics are expected to grow by 3,000.00% in the coming year, from $0.01 to $0.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protalix BioTherapeutics is -11.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protalix BioTherapeutics is -11.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtalix BioTherapeutics has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.74% of the float of Protalix BioTherapeutics has been sold short.Short Interest Ratio / Days to CoverProtalix BioTherapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protalix BioTherapeutics has recently increased by 174.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtalix BioTherapeutics does not currently pay a dividend.Dividend GrowthProtalix BioTherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.74% of the float of Protalix BioTherapeutics has been sold short.Short Interest Ratio / Days to CoverProtalix BioTherapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protalix BioTherapeutics has recently increased by 174.79%, indicating that investor sentiment is decreasing significantly. News and Social Media1.3 / 5News SentimentN/A News SentimentProtalix BioTherapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.08 average news sentiment score of Medical companies.Search InterestOnly 10 people have searched for PLX on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Protalix BioTherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Protalix BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.50% of the stock of Protalix BioTherapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.53% of the stock of Protalix BioTherapeutics is held by institutions.Read more about Protalix BioTherapeutics' insider trading history. Receive PLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PLX Stock News HeadlinesProtalix BioTherapeutics Names Gilad Mamlok Chief Financial OfficerJuly 21, 2025 | marketwatch.comProtalix Biotherapeutics Inc.: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial OfficerJuly 21, 2025 | finanznachrichten.deThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains. | Weiss Ratings (Ad)Protalix BioTherapeutics welcomes new finance chiefJuly 21, 2025 | proactiveinvestors.comPLX | Protalix BioTherapeutics Inc. Annual Cash Flow Statement ...July 10, 2025 | marketwatch.comProtalix BioTherapeutics joins Russell 3000 and 2000 indexes following annual reconstitutionJune 30, 2025 | proactiveinvestors.comProtalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYCMay 14, 2025 | finance.yahoo.comPLX: First Quarter ResultsMay 13, 2025 | msn.comSee More Headlines PLX Stock Analysis - Frequently Asked Questions How have PLX shares performed this year? Protalix BioTherapeutics' stock was trading at $1.88 at the start of the year. Since then, PLX shares have decreased by 20.2% and is now trading at $1.50. How were Protalix BioTherapeutics' earnings last quarter? Protalix BioTherapeutics, Inc. (NYSE:PLX) posted its earnings results on Friday, May, 9th. The company reported ($0.05) EPS for the quarter. Protalix BioTherapeutics had a negative trailing twelve-month return on equity of 30.89% and a negative net margin of 21.03%. When did Protalix BioTherapeutics' stock split? Protalix BioTherapeutics shares reverse split on the morning of Friday, December 20th 2019.The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Protalix BioTherapeutics? Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protalix BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protalix BioTherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/09/2025Today7/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:PLX CIK1006281 Webwww.protalix.com Phone201-696-9345Fax972-4988-9489Employees200Year FoundedN/APrice Target and Rating Average Price Target for Protalix BioTherapeutics$15.00 High Price Target$15.00 Low Price Target$15.00 Potential Upside/Downside+900.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)$0.04 Trailing P/E RatioN/A Forward P/E Ratio150.00 P/E GrowthN/ANet Income$8.31 million Net Margins-21.03% Pretax Margin-21.00% Return on Equity-30.89% Return on Assets-11.74% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.27 Sales & Book Value Annual Sales$59.76 million Price / Sales2.00 Cash Flow$0.08 per share Price / Cash Flow17.80 Book Value$0.47 per share Price / Book3.19Miscellaneous Outstanding Shares79,607,000Free Float68,995,000Market Cap$119.41 million OptionableOptionable Beta-0.23 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NYSE:PLX) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.